TScan Therapeutics Inc. (TCRX)
NASDAQ · Healthcare
TScan Therapeutics Inc. Long Term Debt 2020–2025
TScan Therapeutics Inc. annual long term debt history from 2022 to 2025. Long term debt refers to financial obligations that are due more than one year in the future.
- TScan Therapeutics Inc. long term debt as of December 31, 2025: 32.5M, a 1.44% increase year-over-year.
- TScan Therapeutics Inc. long term debt for 2025 were 32.5M, a 1.44% increase from 2024.
- TScan Therapeutics Inc. long term debt for 2024 were 32.1M, a 6.74% increase from 2023.
- TScan Therapeutics Inc. long term debt for 2023 were 30.0M, a 2.58% increase from 2022.
- TScan Therapeutics Inc. long term debt for 2022 were 29.3M.
Long Term Debt
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| TScan Therapeutics Inc. Annual Long Term Debt (Millions of US $) | |
|---|---|
| 2025 | $33 |
| 2024 | $32 |
| 2023 | $30 |
| 2022 | $29 |
TScan Therapeutics Inc. Long Term Debt — FAQ
TScan Therapeutics Inc. (TCRX) long term debt over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see TCRX's long term debt history?
The chart and table above show TScan Therapeutics Inc.'s long term debt by year and by quarter, including the growth rate.